Yarrow Bioscience, Inc. filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-28. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: David Domzalski, President and Chief Executive Officer, effective 2026-07-27
In addition, each of David Domzalski, VYNE's President and Chief Executive Officer, Iain Stuart, Ph.D., VYNE's Chief Scientific Officer, and Mutya Harsch, VYNE's Chief Legal Officer and General Counsel, resigned as executive officers at the Closing and their employment was terminated effective July 27, 2026, which terminations are considered to be without "cause" related to a change in control for purposes of their offer letters with VYNE.
Appointed: Rebecca Frey, Chief Executive Officer
On July 27, 2026, the Board appointed Rebecca Frey, Pharm.D. as the Company's Chief Executive Officer, Tyler Zeronda as the Company's Chief Financial Officer, Steven Ryder, M.D. as the Company's Chief Medical Officer, Lori Payton, Ph.D. as the Company's Chief Development Officer and Rachael Alford, Ph.D. as the Company's Chief Operating Officer, each to serve at the discretion of the Board.
Find people with the same kind of experience as the President and Chief Executive Officer at Yarrow Bioscience, Inc., with the record behind each one.
Find candidates like President and Chief Executive Officer at Yarrow Bioscience, Inc.New leaders review vendors and budgets in their first months. Get an alert the next time Yarrow Bioscience, Inc. is in the news or changes leadership.
Get an alert when Yarrow Bioscience, Inc. changes leadershipTools for this story
Each opens in a new tab, filled in for Yarrow Bioscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.